

Structure of Leucinostatin A, New Peptide Antibiotic from *Paecilomyces lilacinus* A-267

Yuji Mori,^a Makoto Tsuboi,^a Makoto Suzuki,^{*a} Kazutaka Fukushima,^b and Tadashi Arai^b

^aFaculty of Pharmacy, Meijo University, Nagoya 468, Japan

^bResearch Institute for Chemobiodynamics, Chiba University, Chiba 280, Japan

A new antibiotic leucinostatin A was isolated from the culture filtrate of *Paecilomyces lilacinus* A-267 and its structure was elucidated by mass spectrometric and degradative methods.



The peptide antibiotic leucinostatin isolated from *Paecilomyces lilacinus* A-267 has aroused considerable interest owing to its antitumour activity on Ehrlich solid carcinoma and antibacterial activity against Gram-positive bacteria and a wide range of fungi.¹ A structural study revealed leucinostatin to be a new basic peptide composed of unusual amino-acids: *cis*-4-methyl-L-proline (MePro),² *L*-threo- β -hydroxyleucine (HyLeu),³ and α -aminoisobutyric acid (Aib). In an independent study, Kenner *et al.*⁴ reported the isolation of antibiotic I.C.I. No. 13959 which contains the same amino-acids as leucinostatin but which has not yet been characterized.

Leucinostatin is a mixture of several components which were separated by alumina column chromatography to give mainly leucinostatin A and B. We report here the structure of leucinostatin A.

Leucinostatin A (1), C₆₂H₁₁₁N₁₁O₁₃; m.p. 98–101 °C; $[\alpha]_D^{20}$ –11.0° (c 0.1, MeOH); λ_{max} (EtOH) 202 and 220 (sh) nm; ν_{max} (CHCl₃) 3280 (NH), 1705 (CO), and 1645 (amide CO) cm⁻¹; ¹H n.m.r. (CDCl₃) δ 3.10 (*N,N*-dimethyl), ¹³C n.m.r.

(CDCl₃) δ 211.0 (s, CO), 180–160 (*ca.* 8 \times s, amide CO), and 150.6 and 120.9 p.p.m. (each d, C=C), has a molecular weight of 1217 from its field desorption mass spectrum [f.d.m.s. *m/z* 1218 (*MH*⁺)] and showed a negative reaction for ninhydrin, but a positive Dragendorff reaction. These data indicated that (1) is a basic peptide antibiotic with one ketone carbonyl, one conjugated double bond, and dimethylamino-groups.

Acid hydrolysis (6*N* HCl, 110 °C, 20 h) of (1) followed by amino-acid analysis gave the following results: (HyLeu)₁ (Aib)₂₋₃ (Leu)₂₋₃ (β -Ala)₁ (MePro)₁. Cellulose column chromatography of the hydrolysate gave (*S*)-*N*¹,*N*¹-dimethylpropane-1,2-diamine (2)·2HCl, m.p. 115–117 °C: $[\alpha]_D^{20}$ +9.8° (c 0.12, MeOH); chemical ionization (c.i.) m.s. *m/z* 103 (*MH*⁺); ¹H n.m.r. (CDCl₃) δ 1.50 (3H, d, *J* 6 Hz), 3.00 (6H, s), 3.25–3.65 (2H, m), and 3.95 (1H, m), and an unidentified amino-acid (3). The *S*-configuration of (2) was established by comparison with an authentic sample prepared from Boc-Ala by successive treatment with i, ClCO₂Et, ii, HNMe₂, iii, CF₃CO₂H, and iv, LiAlH₄. The ¹H n.m.r., i.r., and mass



spectra of the amino-acid (3)[†] revealed that (3) is 4-methyl-6-(2-oxobutyl)-2-piperidinecarboxylic acid whose stereochemistry was established by proton spin-decoupling experiments. The structure of (3) corresponds to trichoponic acid obtained by the hydrolysis of trichopolyns.⁵

From the diethyl ether extract of the hydrolysate was isolated (*S*)-(*E*)-4-methylhex-2-enoic acid (4), $[\alpha]_D^{20} + 49.7^\circ$ (*c* 0.25, CHCl_3); m/z 128 (M^+); λ_{max} (EtOH) 207 nm; ν_{max} (CHCl_3) 3600–2400 (OH), 1685 (CO), and 1640 ($\text{C}=\text{C}$) cm^{-1} ; ^1H n.m.r. (CDCl_3) δ 0.89 (3H, t, J 7 Hz), 1.05 (3H, t, J 7 Hz), 1.43 (2H, q, J 7 Hz), 2.26 (1H, m), 5.77 (1H, d, J 16 Hz), and 6.98 (1H, dd, J 16, 8 Hz). Catalytic hydrogenation of (4) afforded a saturated acid, $[\alpha]_D^{20} + 7.6^\circ$ (*c* 0.15, CHCl_3), which is identical to (*S*)-4-methylhexanoic acid (lit.,⁶ $[\alpha]_D^{20} + 7.4^\circ$). Since leucinostatin A (1) is negative for ninhydrin and methylation with CH_2N_2 recovered the starting material the C- and N-termini of (1) could be protected by the diamine (2) and the fatty acid (3), respectively. The u.v. absorptions and ^{13}C n.m.r. chemical shifts of (1) at 150.6 and 120.9 p.p.m. are, therefore, ascribed to the N-terminal α,β -unsaturated amide structure.

Partial hydrolysis (6N HCl, room temp., 40 h) of (1) gave mainly two peptides (5) and (6), and the diamine (2). Hydrolysis with 2N HCl (reflux, 2 h) afforded fragments (7) and (8), the one containing the N-terminal fatty acid and the other the C-terminal diamine. Sequences of the fragments (5)–(8) were determined by dansylation, dansyl-Edman degradation,

(5) HyLeu → Aib → Leu → Leu-Aib-Aib- β -Ala-X

(6) Leu → Aib → Aib- β -Ala-X

(7) FA-MePro

(8) β -Ala-X

Figure 1. Sequences of the fragments (5)–(8) obtained by partial hydrolyses of (1). The methods of determination are indicated as follows; singly underlined: mass spectrometry, doubly underlined: dansylation, arrow: dansyl-Edman analysis. FA = (*S*)-(*E*)-4-methylhex-2-enoic acid (4); X = (*S*)-*N*¹,*N*¹-dimethylpropane-1,2-diamine (2).

c.i.m.s., and ^1H n.m.r. spectroscopy. The results are summarized in Figure 1. As the C- and N-termini of leucinostatin A were blocked with X=[(2)] and FA=[(4)], respectively, the amino-acid (3) should be placed between the fragments (5) and (7). The above-mentioned components constitute a peptide, $\text{C}_{62}\text{H}_{109}\text{N}_{11}\text{O}_{12}$, which corresponds to the dehydration product of leucinostatin A (1).

Alumina treatment of the diacetyl compound obtained by acetylation of (1) gave the *O*-monoacetyl derivative, f.d.m.s. m/z 1264 ($M + \text{Na}^+$) and 1242 ($M\text{H}^+$); ν_{max} (CHCl_3) 1745, 1680, and 1660 cm^{-1} ; ^{13}C n.m.r. (CDCl_3) δ 119.3 (d), 131.6 (d), 144.2 (d), 153.9 (d), and 200.8 (s) p.p.m. The chemical shifts at 131.6, 144.2, and 200.8 p.p.m. can be ascribed to the newly formed α,β -unsaturated ketone system.

These data suggested that the amino-acid (3) is present in (1) as 2-amino-6-hydroxy-4-methyl-8-oxodecanoic acid (9), which, upon hydrolysis, is converted into an α,β -conjugated ketone by elimination of water and then cyclized to (3) by Michael addition.⁵ On the basis of these results, the structure of leucinostatin A can be represented as (1).[‡]

[†] (3): m.p. 197–199 °C (decomp.); $[\alpha]_D^{22} + 8.9^\circ$ (*c* 0.09, MeOH); *c.i.m.s.* m/z 214 ($M\text{H}^+$); ν_{max} (CHCl_3) 3300–2400, 1718, and 1630 cm^{-1} ; 400 MHz ^1H n.m.r. (D_2O) δ 0.96 (d, J 6.6 Hz), C-12-Me), 1.02 (t, J 7.1 Hz, C-10-Me), 1.29 (q, J 14.4 Hz, C-3- H_{ax}), 1.49 (ddd, J 14.4, 11.7, and 4.9 Hz, C-5- H_{ax}), 1.72 (d, J 14.4 Hz, C-5- H_{eq}), 1.92 (m, C-4- H_{ax}), 2.20 (d, J 14.4 Hz, C-3- H_{eq}), 2.57 (q, J 7.1 Hz, C-9-H), 3.05 (dd, J 18.3 and 6.8 Hz, C-7-H), 3.10 (dd, J 18.3 and 6.6 Hz, C-7-H), 3.70 (dd, J 12.2 and 3.7 Hz, C-2- H_{ax}), and 4.12 (m, C-6- H_{eq}).

[‡] Recently the isolation of peptide antibiotics from the *Paecilomyces lilacinus* strain have been reported; see A. Isogai, A. Suzuki, S. Higashikawa, S. Kuyama, and S. Tamura, *Agric. Biol. Chem.*, 1980, **44**, 3029 and 3033; M. Sato, T. Beppu, and K. Arima, *Agric. Biol. Chem.*, *ibid.*, p. 3037.

It is interesting that the amino-acids contained in leucino-statin A are unusual and that the C-terminal linkage of the propanediamine (2) of the antibiotic has not been found previously.

We thank Professor T. Fujita, University of Tokushima, for a generous gift of trichoponamic acid.

Received, 22nd September 1981; Com. 1122

References

- 1 T. Arai, Y. Mikami, K. Fukushima, T. Utsumi, and K. Yazawa, *J. Antibiot.*, 1973, **26**, 157.
 - 2 R. J. Abraham, K. A. McLauchlan, S. Dalby, G. W. Kenner, and R. C. Sheppard, *Nature*, 1961, **192**, 1150; J. S. Dalby, G. W. Kenner, and R. C. Sheppard, *J. Chem. Soc.*, 1962, 4387.
 - 3 S. Dalby, G. W. Kenner, and R. C. Sheppard, *J. Chem. Soc.*, 1960, 968.
 - 4 G. W. Kenner and R. C. Sheppard, *Nature*, 1958, **191**, 48.
 - 5 T. Fujita, Y. Takaishi, A. Okamura, E. Fujita, K. Fuji, N. Hiratsuka, M. Komatsu, and I. Arita, *J. Chem. Soc., Chem. Commun.*, 1981, 585.
 - 6 K. Maskens and N. Polgar, *J. Chem. Soc., Perkin Trans. 1*, 1973, 1909.
-